nitric oxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1948 10102-43-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nitric oxide
  • nitrogen oxide
  • nitrogen monoxide
  • INOmax
A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. It has been shown to have in vitro activity against severe acute res-piratory syndrome corona-virus (SARS-CoV-1) but evidence supporting the use of inhaled nitric oxide in COVID-19 patients is currently limited.
  • Molecular weight: 30.01
  • Formula: NO
  • CLOGP: 0.74
  • LIPINSKI: None
  • HAC: 2
  • HDO: 0
  • TPSA: 34.14
  • ALOGS:
  • ROTB: 0

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Aug. 1, 2001 EMA LINDE HEALTHCARE AB
Dec. 23, 1999 FDA INO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intraventricular haemorrhage neonatal 145.05 65.27 20 1819 161 63487022
Patent ductus arteriosus 118.87 65.27 27 1812 4223 63482960
Oxygen saturation decreased 116.90 65.27 55 1784 88530 63398653
Device failure 89.64 65.27 23 1816 5988 63481195
Hypoxia 84.57 65.27 39 1800 59753 63427430
Product use issue 74.85 65.27 57 1782 220463 63266720
Pulmonary hypertensive crisis 66.12 65.27 11 1828 333 63486850

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product use issue 195.12 63.03 84 1695 63132 34892020
No adverse event 143.53 63.03 51 1728 22876 34932276
Device delivery system issue 140.52 63.03 24 1755 477 34954675
Oxygen saturation decreased 135.15 63.03 62 1717 53756 34901396
Device issue 89.62 63.03 29 1750 9748 34945404
Off label use 80.75 63.03 102 1677 419422 34535730
Neonatal disorder 73.19 63.03 15 1764 815 34954337
Device failure 72.27 63.03 18 1761 2358 34952794
Product use in unapproved indication 69.25 63.03 53 1726 117446 34837706
Pulmonary hypertension 68.12 63.03 29 1750 20895 34934257
Pulmonary haemorrhage 64.63 63.03 23 1756 10281 34944871
Device malfunction 64.38 63.03 23 1756 10398 34944754

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product use issue 290.16 51.14 136 2286 209686 79532280
Oxygen saturation decreased 142.46 51.14 72 2350 128975 79612991
Product use in unapproved indication 138.93 51.14 89 2333 250270 79491696
Off label use 126.27 51.14 145 2277 907070 78834896
Hypoxia 89.27 51.14 49 2373 103194 79638772
Device failure 82.81 51.14 22 2400 6239 79735727
Cardiac arrest 80.19 51.14 55 2367 172041 79569925
Drug ineffective for unapproved indication 75.75 51.14 35 2387 51203 79690763
Right ventricular failure 71.95 51.14 27 2395 23470 79718496
Pulmonary hypertension 68.44 51.14 32 2390 48048 79693918
No adverse event 66.41 51.14 29 2393 37163 79704803
Device delivery system issue 63.56 51.14 12 2410 719 79741247
Drug ineffective 57.10 51.14 110 2312 1080803 78661163
Pulmonary haemorrhage 56.55 51.14 20 2402 14697 79727269
Device issue 54.51 51.14 23 2399 27085 79714881
Pulmonary arterial hypertension 53.51 51.14 23 2399 28343 79713623

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R07AX01 RESPIRATORY SYSTEM
OTHER RESPIRATORY SYSTEM PRODUCTS
OTHER RESPIRATORY SYSTEM PRODUCTS
Other respiratory system products
FDA PE N0000009909 Vasodilation
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D000975 Antioxidants
MeSH PA D001993 Bronchodilator Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D045462 Endothelium-Dependent Relaxing Factors
MeSH PA D016166 Free Radical Scavengers
MeSH PA D064426 Gasotransmitters
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D019141 Respiratory System Agents
MeSH PA D014665 Vasodilator Agents
FDA EPC N0000175940 Vasodilator
CHEBI has role CHEBI:25512 neurotransmitters
CHEBI has role CHEBI:35523 bronchodilator
CHEBI has role CHEBI:35620 vasodilator agents
CHEBI has role CHEBI:48578 free radical scavengers
CHEBI has role CHEBI:62488 signal molecules
CHEBI has role CHEBI:75771 Mus musculus metabolites
CHEBI has role CHEBI:76971 Escherichia coli metabolites
CHEBI has role CHEBI:77746 Homo sapiens metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pulmonary hypertension indication 70995007 DOID:6432
Persistent pulmonary hypertension of the newborn indication 233815004 DOID:13042
Methemoglobinemia contraindication 38959009 DOID:10783
Left heart failure contraindication 85232009
Congenital Heart Defect Requiring Open Patent Ductus Arteriosus contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
800PPM GENOSYL VERO BIOTECH INC N202860 Dec. 20, 2019 RX GAS INHALATION 10124142 Aug. 18, 2025 A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT
800PPM GENOSYL VERO BIOTECH INC N202860 Dec. 20, 2019 RX GAS INHALATION 11383059 Aug. 18, 2025 A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT
800PPM GENOSYL VERO BIOTECH INC N202860 Dec. 20, 2019 RX GAS INHALATION 11554241 Aug. 18, 2025 A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT
800PPM GENOSYL VERO BIOTECH INC N202860 Dec. 20, 2019 RX GAS INHALATION 8226916 Aug. 18, 2025 A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT
800PPM GENOSYL VERO BIOTECH INC N202860 Dec. 20, 2019 RX GAS INHALATION 8609028 Aug. 18, 2025 A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT
800PPM GENOSYL VERO BIOTECH INC N202860 Dec. 20, 2019 RX GAS INHALATION 9956373 Aug. 18, 2025 A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT
800PPM GENOSYL VERO BIOTECH INC N202860 Dec. 20, 2019 RX GAS INHALATION 10814092 Oct. 17, 2025 A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT
800PPM GENOSYL VERO BIOTECH INC N202860 Dec. 20, 2019 RX GAS INHALATION 8057742 Jan. 18, 2026 A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT
800PPM GENOSYL VERO BIOTECH INC N202860 Dec. 20, 2019 RX GAS INHALATION 7947227 Oct. 17, 2026 A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT
100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 DISCN GAS INHALATION 8282966 June 30, 2029 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 DISCN GAS INHALATION 8293284 June 30, 2029 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 DISCN GAS INHALATION 8431163 June 30, 2029 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 DISCN GAS INHALATION 8795741 June 30, 2029 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 DISCN GAS INHALATION 8846112 June 30, 2029 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
800PPM INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 RX GAS INHALATION 8282966 June 30, 2029 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
800PPM INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 RX GAS INHALATION 8293284 June 30, 2029 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
800PPM INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 RX GAS INHALATION 8431163 June 30, 2029 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
800PPM INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 RX GAS INHALATION 8795741 June 30, 2029 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
800PPM INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 RX GAS INHALATION 8846112 June 30, 2029 A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
800PPM GENOSYL VERO BIOTECH INC N202860 Dec. 20, 2019 RX GAS INHALATION 9604028 Aug. 13, 2029 A METHOD FOR DELIVERING NITRIC OXIDE TO A PATIENT WITH PULMONARY HYPERTENSION OR HYPOXIA
100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 DISCN GAS INHALATION 8291904 Jan. 6, 2031 A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT
100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 DISCN GAS INHALATION 8573210 Jan. 6, 2031 A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 DISCN GAS INHALATION 8776794 Jan. 6, 2031 A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT
100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 DISCN GAS INHALATION 8776795 Jan. 6, 2031 A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT
800PPM INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 RX GAS INHALATION 8291904 Jan. 6, 2031 A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT
800PPM INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 RX GAS INHALATION 8573210 Jan. 6, 2031 A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
800PPM INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 RX GAS INHALATION 8776794 Jan. 6, 2031 A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT
800PPM INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 RX GAS INHALATION 8776795 Jan. 6, 2031 A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT
800PPM INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 RX GAS INHALATION 9265911 Jan. 6, 2031 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
800PPM INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 RX GAS INHALATION 9295802 Jan. 6, 2031 A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT
800PPM INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 RX GAS INHALATION 9408993 Jan. 6, 2031 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
800PPM INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 RX GAS INHALATION 9279794 Feb. 19, 2034 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY COMPENSATING LONG-TERM SENSITIVITY DRIFT OF ELECTROCHEMICAL GAS SENSORS USED IN SYSTEMS FOR DELIVERING THERAPEUTIC NITRIC OXIDE TO A PATIENT
800PPM INOMAX MALLINCKRODT HOSP N020845 Dec. 23, 1999 RX GAS INHALATION 9770570 May 3, 2036 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY MEASURING AND DISPLAYING AN INDICATION OF THE CALCULATED DELIVERY CONCENTRATION OF NITRIC OXIDE AS COMPARED TO THE DESIRED DELIVERY CONCENTRATION OF NITRIC OXIDE
800PPM GENOSYL VERO BIOTECH INC N202860 Dec. 20, 2019 RX GAS INHALATION 11672938 July 22, 2040 A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Soluble guanylate cyclase Enzyme ACTIVATOR CHEMBL CHEMBL

External reference:

IDSource
31C4KY9ESH UNII
4021248 VUID
N0000148689 NUI
D00074 KEGG_DRUG
4021248 VANDF
C0028128 UMLSCUI
CHEBI:16480 CHEBI
NO PDB_CHEM_ID
CHEMBL1200689 ChEMBL_ID
145068 PUBCHEM_CID
DB00435 DRUGBANK_ID
D009569 MESH_DESCRIPTOR_UI
405139 RXNORM
17479 MMSL
47106 MMSL
d04508 MMSL
012088 NDDF
409378005 SNOMEDCT_US
6710000 SNOMEDCT_US
CHEMBL1234579 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Noxivent 101 HUMAN PRESCRIPTION DRUG LABEL 1 59579-101 GAS 100 mg RESPIRATORY (INHALATION) ANDA 16 sections
Noxivent 101 HUMAN PRESCRIPTION DRUG LABEL 1 59579-101 GAS 100 mg RESPIRATORY (INHALATION) ANDA 16 sections
Noxivent 102 HUMAN PRESCRIPTION DRUG LABEL 1 59579-102 GAS 800 mg RESPIRATORY (INHALATION) ANDA 16 sections
Noxivent 102 HUMAN PRESCRIPTION DRUG LABEL 1 59579-102 GAS 800 mg RESPIRATORY (INHALATION) ANDA 16 sections
INOmax HUMAN PRESCRIPTION DRUG LABEL 1 64693-002 GAS 0.98 mg RESPIRATORY (INHALATION) NDA 23 sections
INOmax HUMAN PRESCRIPTION DRUG LABEL 1 64693-002 GAS 0.98 mg RESPIRATORY (INHALATION) NDA 23 sections
INOMAX HUMAN PRESCRIPTION DRUG LABEL 1 64693-003 GAS 6 mg RESPIRATORY (INHALATION) NDA 23 sections
Nitric Oxide Nitrogen Mix HUMAN PRESCRIPTION DRUG LABEL 2 67989-011 GAS 5 mL RESPIRATORY (INHALATION) unapproved medical gas 1 sections
GENOSYL HUMAN PRESCRIPTION DRUG LABEL 1 72385-001 GAS 0.98 mg RESPIRATORY (INHALATION) NDA 23 sections
GENOSYL HUMAN PRESCRIPTION DRUG LABEL 1 72385-001 GAS 0.98 mg RESPIRATORY (INHALATION) NDA 23 sections
GENOSYL HUMAN PRESCRIPTION DRUG LABEL 1 72385-002 GAS 0.98 mg RESPIRATORY (INHALATION) NDA 24 sections
NOW st HUMAN OTC DRUG LABEL 1 80519-301 LIQUID 1.12 g TOPICAL unapproved drug other 12 sections
NOW st HUMAN OTC DRUG LABEL 1 80519-301 LIQUID 1.12 g TOPICAL unapproved drug other 12 sections
IBSIBD NO 180 Start (Helps improve intestinal healthy and immunity, Lettuce and Soybean fermented powder) HUMAN OTC DRUG LABEL 1 83202-1405 CAPSULE 500 mg TOPICAL unapproved drug other 8 sections
NO MORE DRIP FOR NOSE COMFORT (Relieves nasal congestion, sinus congestion, rehydrate nasal passages, allergy relief, concentrated lettuce fermentation) HUMAN OTC DRUG LABEL 1 83202-1469 LIQUID 10 mg TOPICAL unapproved drug other 6 sections
Dr. GNO Deep Moisturizing Essence (Brightening, Wrinckle care, and Moisturizing effect, Acne Treatment, Fermented Cabbage Extract, Mesoporous Silica Nanoparticle, Zinc, Gold) HUMAN OTC DRUG LABEL 1 83202-1583 LIQUID 40 mg TOPICAL unapproved drug other
Top NO Doctors (Helps improve matabolic disorder, Bean sprout powder) HUMAN OTC DRUG LABEL 1 83202-1766 TABLET 100 mg TOPICAL unapproved drug other 6 sections
Dr. GNO Refreshing Mist (For skin care, and dry skin, safe to use it in the eye, Acne treatment, Fermented Sunflower seed Extract) HUMAN OTC DRUG LABEL 1 83202-1857 LIQUID 50 mg TOPICAL unapproved drug other 6 sections
Dr. GNO CLEANSER (Helps cleanse sensitive skin, clears skin troubles, especially acne, fermented cabbage extract, mesoporous silica nanoparticle, zinc) HUMAN OTC DRUG LABEL 1 83202-2139 SOAP 50 mg TOPICAL unapproved drug other 6 sections
Dr. GNO All Care 500 (Brightening, Wrinckle care, and Moisturizing effect, Pain relief, Acne Treatment, Fermented Cabbage Extract) HUMAN OTC DRUG LABEL 1 83202-2149 LIQUID 400 mg TOPICAL unapproved drug other 1 sections
NO more Eye Pain (Relieves dryness of the eye, Protects against irritaion of the eye) redness of the eye, Concentrated Cabbage fermentation solubles) HUMAN OTC DRUG LABEL 1 83202-2278 LIQUID 5 mg TOPICAL unapproved drug other 6 sections
NO Care (Helps improve matabolic disorder, Lettuce fermented powder) HUMAN OTC DRUG LABEL 1 83202-2288 CAPSULE 100 mg TOPICAL unapproved drug other 3 sections
Dr. GNO Deep Moisturizing Mist (Brightening, Wrinckle care, and Moisturizing effect, Acne Treatment, Fermented Cabbage Extract, Mesoporous Silica Nanoparticle, Zinc, Gold) HUMAN OTC DRUG LABEL 1 83202-2349 LIQUID 12 mg TOPICAL unapproved drug other
Dr. GNO Essence (Brightening, Wrinckle care, and Moisturizing effect, Acne treatment, Fermented Lettuce Extract) HUMAN OTC DRUG LABEL 1 83202-2922 LIQUID 10 mg TOPICAL unapproved drug other 6 sections
Dr. GNO Recovery Oil (Brightening, Wrinckle care, and Moisturizing effect, Acne Treatment, Fermented Cabbage Extract) HUMAN OTC DRUG LABEL 1 83202-2952 LIQUID 8 mg TOPICAL unapproved drug other 6 sections
Bio NO Pharm V (Helps improve metabolic disorder and immunity, Lettuce fermented powder) HUMAN OTC DRUG LABEL 1 83202-3285 CAPSULE 100 mg TOPICAL unapproved drug other 6 sections
Dr. GNO Deep Moisturizing Cream (Brightening, Wrinckle care, and Moisturizing effect, Acne Treatment, Fermented Cabbage Extract, Mesoporous Silica Nanoparticle, Zinc, Gold) HUMAN OTC DRUG LABEL 1 83202-3585 LIQUID 30 mg TOPICAL unapproved drug other
OIC Premium NO 365 (Helps improve matabolic disorder, Bean sprout powder) HUMAN OTC DRUG LABEL 1 83202-3751 CAPSULE 100 mg TOPICAL unapproved drug other 6 sections
Dr. GNO All Care 200 (Brightening, Wrinckle care, and Moisturizing effect, Pain relief, Acne Treatment, Fermented Cabbage Extract) HUMAN OTC DRUG LABEL 1 83202-5147 LIQUID 100 mg TOPICAL unapproved drug other 6 sections
Hexalong NO (Helps hematopoiesis and immunity, Hexalong fermented powder) HUMAN OTC DRUG LABEL 1 83202-5578 TABLET 100 mg TOPICAL unapproved drug other 6 sections